Oncoinvent’s Radspherin clears first randomized safety review
Oncoinvent’s alpha radiopharmaceutical Radspherin has shown no treatment-related serious adverse events in the first interim safety analysis of its ongoing randomized Phase 2 trial in ovarian cancer.
The RAD-18-003 trial is testing a single dose of Radspherin, given into the abdominal cavity after surgery, on top of standard of care in patients with peritoneal metastases from advanced ovarian cancer. As of 30 October, 74 patients had been randomized 2:1 to Radspherin or standard of care alone. The safety analysis covered 56 patients, 40 of whom received Radspherin.
There were no deaths and no treatment discontinuations, and the share of patients with adverse events was similar in both arms. Ten events in five Radspherin-treated patients were considered possibly related to the treatment, all mild or moderate. The trial’s Independent Data Monitoring Committee reviewed the unblinded data on 13 November and recommended continuing the trial without modification.
Recruitment is expected to be completed in the first half of 2027. An interim efficacy readout is planned for April 2027.
“These first randomized data are an important milestone for Oncoinvent and for the Radspherin program,” says Zuzana Jirakova Trnkova, Chief Medical Officer of Oncoinvent.
Updated: November 18, 2026, 03:10 pm
Published: November 17, 2026
